Acelrx announces an investigator-initiated study of dsuvia® in the emergency department for patients with sickle cell disease

Hayward, calif., may 20, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at tampa general hospital to evaluate the use of dsuvia for patients with sickle cell disease presenting to the emergency department (ed) with painful vaso-occlusive crisis (voc).
ACRX Ratings Summary
ACRX Quant Ranking